Technical notes, application notes, posters, and protocols that feature Combinati technology across various research areas, key applications, and assay scale.
- All
- Infectious Disease
- Oncology
- Reproductive Health
- All
- Infectious Disease
- Oncology
- Reproductive Health
Combinati |Q| SARS-CoV-2 Triplex Assay for sensitive detection of viral RNA targets
The COVID-19 pandemic has drawn heightened concern, with over eleven million positive SARS-CoV-2 cases confirmed worldwide by July 2020. 1 RT-qPCR currently serves as the clinical standard for the diagnosis of COVID-19.
Discriminatory 11-Plex Assay Designed to Monitor Estrogen Receptor Mutations Using a Novel, Melt-Analysis Capable Digital PCR Platform
In a large fraction of ER+/HER2- metastatic breast cancer (MBC), treatment with aromatase inhibitors fails due to emerging resistance. A
key mechanism of this resistance is associated with a set of missense mutations in the gene encoding for the estrogen receptor (ESR1). We
have developed a multiplex, quantitative, Research Use Only assay for the detection and identification of 11 ESR1 single nucleotide polymorphisms (SNPs) and the ESR1 gene in a single reaction, using patented, melt-based chemistry and an innovative digital PCR (dPCR) system.
Fully Integrated Single Instrument Imaging-based Digital PCR Platform
Digital PCR (dPCR) has gained popularity in recent years for cancer research such as rare
mutation detection, minimal residual disease, treatment selection, and recurrence monitoring. However, currently available technologies suffer from several limitations such as tedious workflow, long time-to-result, poor multiplexity, and inconsistent reagent digitization, which has severely hindered its broad adoption. We have designed and manufactured a dPCR platform that is capable of consistent sample digitization, thermal cycling and simultaneous interrogation of 20,000 partitions with walk-away workflow.
Combinati |Q| SARS-CoV-2 Digital PCR Test Protocol
The Combinati Absolute Q provides a walkaway digital PCR workflow. Considering all steps including reverse transcription are completed in under 90 minutes, the Absolute Q provides the fastest time-to answer digital PCR workflow for precise quantification of viral reference material.
1-Step RT-dPCR in under 80 Minutes on the Combinati Absolute Q
The Absolute Q dPCR platform and its 80-minute 1-step RT-dPCR technology have broad implications for characterizing infectious diseases beyond COVID-19. The versatile platform can be adapted to a wide range of nucleic acid detection applications requiring absolute quantification.
Experiment Flexibility with the Combinati™ Absolute Q Digital PCR Platform
Microfluidic Array Partitioning (MAP) technology utilizes fixed microchamber arrays and positive pneumatic pressure to partition reagents and perform digital PCR, instead of using fluid-shearing to generate droplets.
SARS-CoV-2 Reference Material Quantification on the Absolute Q dPCR Platform
To address the need for a reliable method of accurate and precise measurements of SARS-CoV-2 samples, we leverage the Combinati Absolute Q Digital PCR (dPCR) platform, to quantify commercially available SARS-CoV-2 reference control material.
IDT rhAmp EGFR p.T790M Genotyping on the Combinati Absolute Q
Integrated DNA Technologies’ rhAmp SNP Genotyping System enables highly precise interrogation of SNPs within difficult genomic regions. For the first time, the IDT rhAmp assay performance was demonstrated on a digital PCR platform — quantifying EGFR p.T790M mutation down to 0.1%.
BCR/ABL Gene Expression Assay on the Combinati Absolute Q
95% of Chronic Myeloid Leukemia (CML) cases are characterized by the presence of a BCR-ABL1 fusion gene. Regular monitoring involving precise quantification of BCR-ABL1 transcripts is integral to successful tyrosine kinase inhibitor (TKI) treatment. Read more about how samples with precise ratios of BCR-ABL1/ABL1 were created and confirmed on the Combinati dPCR platform.
Quadruplex Absolute Q Digital PCR for Spinal Muscular Atrophy (SMA) Screening
Spinal muscular atrophy (SMA), a genetic neuromuscular disorder and leading genetic cause of infant mortality. Here we describe a 4-color multiplexing digital PCR solution on the Combinati Absolute Q to meet the growing demand for rapid SMA newborn screening and treatment.
TaqMan™ Liquid Biopsy assays for rare target quantification
Digital PCR (dPCR) enables rare target detection even in the presence of high non-target background. Read more about how the Applied Biosystems™ TaqMan™ Liquid Biopsy dPCR Assays were used to perform rare target detection for 5 hot-spot cancer mutations on the Combinati Absolute Q platform.
